Physician profile
Frederick Weeks
NPI 1225030471
$683.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $128 · 2021: $330 · 2022: $19.22 · 2024: $23.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $108.10 | 2019-2021 | |
| Janssen Biotech, INC. | $92.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $44.83 | 2019-2021 | |
| Abbvie INC. | $41.25 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $39.68 | 2021 | |
| Lilly USA, LLC | $35.88 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $34.68 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $32.99 | 2019-2021 | |
| Coherus Oncology, INC. | $30.30 | 2021 | |
| Pfizer INC. | $27.92 | 2020-2021 | |
| Celgene Corporation | $23.34 | 2021 | |
| Beigene USA, INC. | $21.86 | 2021 | |
| Astellas Pharma US INC | $19.04 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.06 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $16.66 | 2019 | |
| Amgen INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.